United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Crystalys Therapeutics doses first patients in Fortress Biotech’s global Phase 3 gout trial of Dotinurad, targeting safer uric acid control Find out how Fortress Biotech’s Dotinurad is advancing in global Phase 3 trials and why it could redefine gout therapy worldwide. bySoujanya RaviOctober 21, 2025